“破壁者”宋瑞霖：乐意为医药创新鼓与呼 ｜ 我们的四分之一世纪

Core Insights - The article highlights the significant contributions of Song Ruilin to the Chinese pharmaceutical industry over the past 25 years, portraying him as a transformative figure who has bridged gaps between policy and industry needs [4][19]. Group 1: Song Ruilin's Background and Role - Song Ruilin, born in 1962, transitioned from a government role to lead the China Pharmaceutical Innovation Promotion Association (CPIA) for 16 years, becoming a key advocate for pharmaceutical innovation in China [4][19]. - He is recognized for his unique position as a non-pharmaceutical professional leading an industry association, emphasizing the importance of understanding industry challenges [17][19]. Group 2: Key Contributions to Policy and Reform - Song played a crucial role in the drafting of the 2017 policy aimed at reforming drug approval processes, which significantly impacted the pharmaceutical industry by addressing systemic bottlenecks [8][9]. - He highlighted the inefficiencies in clinical trial approvals, advocating for a more streamlined process that could save Chinese pharmaceutical companies 4 to 5 years compared to international standards [9][10]. - His involvement in the introduction of the 18A listing rule on the Hong Kong Stock Exchange in 2018 marked a pivotal moment for Chinese biotech companies, facilitating their access to capital [15][16]. Group 3: Advocacy and Industry Representation - Song's leadership in the CPIA transformed it into a credible voice for the pharmaceutical industry, challenging government policies that were seen as detrimental to market fairness [20][21]. - He emphasized the need for a robust patent protection system to support innovation, arguing that the lack of such a system hindered the growth of the domestic pharmaceutical sector [11][12]. Group 4: International Engagement and Standards - Under Song's leadership, the CPIA joined the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), aligning China's drug regulatory standards with international norms [12][14]. - His international visits and insights into global pharmaceutical practices have helped bridge the gap between Chinese pharmaceutical companies and international markets [13][14]. Group 5: Personal Philosophy and Future Outlook - Song believes in the importance of open dialogue and constructive criticism, viewing them as essential for the evolution of the pharmaceutical industry [26]. - He remains committed to contributing to policy discussions and reforms, reflecting a sense of responsibility towards the industry's future [23][24].